Other Territory Sample Clauses

Other Territory. For countries within the Other Territory, the party having exclusive marketing rights in any such country shall also have rights to manufacture Collaboration Products for sale in such country, unless otherwise agreed by the parties.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Other Territory. 11 5.4 Use of Clinical Data.............................................................................11 5.5
Sample 1Sample 2See All (4)
Other Territory. 14 7.5 Sublicensees.....................................................................................14 7.6 Covenants........................................................................................14
Sample 1Sample 2
Other Territory. 2- 12.5 Supply Agreements................................................................................2-
Sample 1Sample 2
Other Territory. 14 -i- 3 TABLE OF CONTENTS (CONTINUED)
Sample 1
Other Territory. 14 -i- 3 TABLE OF CONTENTS (CONTINUED) PAGE ---- 7.5 Sublicensees........................................... 15 7.6 Covenants.............................................. 15
Sample 1
Other Territory. [*] [*] Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Sample 1
AutoNDA by SimpleDocs
Other Territory. The Parties understand that in certain countries outside the Major Territories, such third party verification may not be possible, or may be possible only with the expenditure of significant funds. In such cases, the parties shall rely upon a mutually agreed proxy for sales in such country (e.g. verifiable sales in a similar market).
Sample 1
Other Territory indicates this country is subject to the provisions of Section 4.6 Afghanistan Kiribati Bahrain Kuwait* Bangladesh Kyrgyz Bhutan Laos Brunei Lebanon* Cambodia Malaysia ***Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. CONFIDENTIAL TREATMENT REQUESTED BY NOVABAY PHARMACEUTICALS, INC. China, The People’s Republic (including Hong Kong and Macao) Maldives Xxxx Islands Xxxxxxxx Islands East Timor Micronesia Fiji Mongolia India Myanmar Indonesia Nauru Iran Nepal Iraq Niue Israel* North Korea Jordan* Oman Kazakhstan Pakistan Palau Taiwan (Republic of China) Palestine* Tajikistan Papua New Guinea Thailand Philippines Tonga Qatar Turkey* Samoa Turkmenistan Saudi Arabia* Tuvalu Singapore United Arab Emirates* ***Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. CONFIDENTIAL TREATMENT REQUESTED BY NOVABAY PHARMACEUTICALS, INC. Solomon Islands Uzbekistan South Korea Vanuatu Sri Lanka Viet Nam Syria* Yemen ***Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. CONFIDENTIAL TREATMENT REQUESTED BY NOVABAY PHARMACEUTICALS, INC. SCHEDULE A ASIA - PACIFIC Bangladesh Tonga Bhutan Tuvalu Brunei Vanuatu Cambodia Viet Nam China, The People’s Republic (including Hong Kong and Macao) Xxxx Islands East Timor Fiji India Indonesia Kiribati Laos Malaysia Maldives Xxxxxxxx Islands Micronesia Mongolia Myanmar Nauru ***Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. CONFIDENTIAL TREATMENT REQUESTED BY NOVABAY PHARMACEUTICALS, INC. Nepal Niue North Korea Palau Papua New Guinea Philippines Samoa Singapore Solomon Islands South Korea Sri Lanka Taiwan (Republic of China) Thailand ***Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. SCHEDULE A [Attached behind] CONFIDENTIAL TREATMENT REQUESTED BY NOVABAY PHARMACEUTICALS, INC. ***Confidential treatment requested p...
Sample 1

Related to Other Territory

  • Territory The territorial limits of this Agreement shall be identical with those of the Reinsured Contracts.

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Country Risk – shall have the meaning set forth in the Custodian Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.